An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles

Cancer Immunology, Immunotherapy

Volumn 58, Issue 11, 2009, Pages 1879-1887

  Terasaki, Yasunobu ^a,b   Shichijo, Shigeki ^a   Niu, Yamei ^a   Komatsu, Nobukazu ^a   Noguchi, Masanori ^a   Todo, Satoru ^b   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

HLA; Immunotherapy; Peptide vaccine; Prostate acid phosphatase

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BETA TUBULIN; EPSTEIN BARR VIRUS ANTIGEN 2; EPSTEIN BARR VIRUS ANTIGEN 24; HLA A ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A26 ANTIGEN; HLA A3 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN A2; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN A24; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN IEX1; LECTIN; NONSTRUCTURAL PROTEIN 3; PEPTIDE VACCINE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN KINASE LCK; PROTEIN PAP; PROTEIN SART3; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; ACID PHOSPHATASE; PEPTIDE FRAGMENT;

ALLELE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER CELL; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; HUMAN; HUMAN CELL; MALE; PEPTIDE ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; CYTOTOXICITY TEST; ENZYMOLOGY; GENETICS; IMMUNOLOGY; PROSTATE; TUMOR CELL LINE;

ACID PHOSPHATASE; ALLELES; CELL LINE, TUMOR; CYTOTOXICITY TESTS, IMMUNOLOGIC; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HLA-A3 ANTIGEN; HUMANS; MALE; PEPTIDE FRAGMENTS; PROSTATE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 70349773411     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0699-2     Document Type: Article

References (38)

1. M Barve J Bender N Senzer C Cunningham A Greco D McCune R Steis H Khong D Richards J Stephenson P Ganesa J Nemunaitis G Ishioka B Pappen M Nemunaitis M Morse B Mills PB Maples J Sherman JJ Nemunaitis 2008 Induction of immune response and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer J Clin Oncol 27 4418 4425
2. JH Sampson GE Archer DD Bigner T Davis HS Friedman T Keler DA Mitchell DA Reardon R Sawaya AB Heimberger 2008 Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. Abstract of Annual Meeting of American Society of Clinical Oncology J Clin Oncol 26 2011 page 92s
3. CL Slingluff Jr GR Petroni KA Chianese-Bullock ME Smolkin S Hibbitts C Murphy N Johansen WW Grosh GV Yamshchikov PY Neese JW Patterson R Fink PK Rehm 2007 Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting Clin Cancer Res 13 6386 6395
4. M Noguchi K Kobayashi N Suetsugu K Tomiyasu S Suekane A Yamada K Itoh S Noda 2003 Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination Prostate 57 80 92
5. M Noguchi T Mine A Yamada Y Obata K Yoshida J Mizoguchi M Harada S Suekane K Itoh K Matsuoka 2007 Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients. An analysis of prognostic factors in the treatment Oncol Res 16 341 349
6. K Itoh A Yamada 2006 Personalized peptide vaccines. A new therapeutic modality for cancer Cancer Sci 97 970 976
7. D Nagorsen E Thiel 2008 HLA typing demands for peptide-based anti-cancer vaccine Cancer Immunol Immunotherapy 57 1903 1910
8. A Sette J Sidney 1999 Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism Immunogenetics 50 201 212
9. 109-118 peptide to induce cytotoxic T-lymphocytes from prostate cancer patients with HLA class I-A11, -A31, and -A33 alleles Int J Oncol 34 529 536
10. S Matsueda H Takedatsu A Yao M Tanaka M Noguchi K Itoh M Harada 2005 Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles Clin Cancer Res 11 6933 6943
11. H Takedatsu S Shichijo K Katagiri H Sawamizu M Sata K Itoh 2004 Identification of peptide vaccine candidates sharing among HLA-A3+, -A11+, -A31+, and -A33+ cancer patients Clin Cancer Res 10 1112 1120
12. T Minami S Matsueda H Takedatsu M Tanaka M Noguchi H Uemura K Itoh M Harada 2007 Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles Cancer Immunol Immunotherapy 56 689 698
13. S Matsueda H Takedatsu T Sasada K Azuma M Noguchi S Shichijo K Itoh M Harada 2007 New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles J Immunotherapy 30 274 281
14. M Naito Y Komohara Y Ishihara M Noguchi Y Yamashita T Shirakusa A Yamada K Itoh M Harada 2007 Identification of Lck-derived peptides applicable to anti-cancer vaccine for patients with human leukocyte antigen-A3 supertype alleles Br J Cancer 97 1648 1654
15. Y Wang M Harada H Yano S Ogasawara H Takedatsu Y Arima S Matsueda A Yamada K Itoh 2005 Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma J Immunotherapy 28 535 541
16. BK Hoa NTL Hang K Kashiwase J Ohashi LT Lien T Horie J Shojima M Hijikata S Sakurada M Satake K Tokunaga T Sasazuki N Keicho 2007 HLA-A, -B, -C, -DRB1 alleles and haplotypes in the Kinh population in Vietnam Tissue Antigens 71 127 134
17. B Carlsson O Forsberg M Bengtsson TH Tötterman M Essand 2007 Characterization of human prostate and breast cancer cell lines for experimental T cell-based immunotherapy Prostate 67 389 395
18. M Oiso M Eura F Katsura M Takiguchi Y Sobao K Masuyama M Nakashima K Itoh T Ishikawa 1999 A newly identified MAGE-3-derived epitope recognized by HLA-A24-restricted cytotoxic T lymphocytes Int J Cancer 81 387 394
19. NM Steven NE Annels A Kumar AM Leese MG Kurilla AB Rickinson 1997 Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response J Exp Med 185 1605 1617
20. SP Lee RJ Tierney WA Thomas JM Brooks AB Rickinson 1997 Conserved CTL epitopes within EBV latent membrane protein 2 A potential target for CTL-based tumor therapy J Immunol 158 3325 3334
21. KC Parker MA Bednarek LK Hull U Utz B Cunningham HJ Zweerink WE Biddison JE Coligan 1992 Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2 J Immunol 149 3580 3587
22. Y Ikeda-Moore H Tomiyama K Miwa S Oka A Iwamoto Y Kaneko M Takiguchi 1997 Identification and characterization of multiple HLA-A24-restricted HIV-1 CTL epitopes: strong epitopes are derived from V regions of HIV-1 J Immunol 159 6242 6252
23. C Neumann-Haefelin T Killinger J Timm S Southwood D McKinney HE Blum R Thimme 2007 Absence of viral escape within a frequently recognized HLA-A26-restricted CD8+ T-cell epitope targeting the functionally constrained hepatitis C virus NS5A/5B cleavage site J Gen Virol 88 1986 1991
24. J Sidney B Peters N Frahm C Brander A Sette 2008 HLA class I supertypes: a revised and updated classification BMC Immunol 9 1
25. H Torikai Y Akatsuka H Miyauchi S Terakura M Onizuka K Tsujimura K Miyamura Y Morishima Y Kodera K Kuzushima T Takahashi 2007 The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206 Bone Marrow Transpl 40 165 174
26. HG Rammensee K Flak O Rotzschke 1993 Peptides naturally presented by MHC class I molecules Annu Rev Immunol 11 213 244
27. MF Guercio J Sidney G Hermanson C Perez HM Grey RT Kubo A Sette 1995 Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype J Immunol 154 685 693
28. R Maier K Falk O Rotzschke B Maier V Gnau S Stevanovic G Jung HG Rammensee A Meyerhans 1994 Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing Immunogenetics 40 306 308
29. EJ Small P Fratesi DM Reese G Strang R Laus MV Peshwa FH Valone 2000 Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells J Clin Oncol 18 3894 3903
30. JI Epstein FP Kuhajda PH Lieberman 1986 Prostate-specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder Hum Pathol 17 939 942
31. N Kimura N Sasano 1986 Prostate-specific acid phosphatase in carcinoid tumors Virchows Arch A Pathol Anat Histopathol 410 247 251
32. Y Kaneko N Motoi A Matsui T Motoi T Oka R Machinami K Kurokawa 1995 Neuroendocrine tumors of the liver and pancreas associated with elevated serum prostatic acid phosphatase Intern Med 34 886 891
33. K Seki S Miyakoshi GH Lee H Matsushita Y Mutoh K Nakase M Ida H Taniguchi 2004 Prostatic acid phosphatase is a possible tumor marker for intravascular large B-cell lymphoma Am J Surg Pathol 28 1384 1388
34. Y Inoue Y Takaue M Takei K Kato S Kanai Y Harada K Tobisu M Noguchi T Kakizoe K Itoh H Wakasugi 2001 Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide J Urol 166 1508 1513
35. S Kamoshida Y Tsutsumi 1990 Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland Hum Pathol 21 1108 1111
36. SL Tepper J Jagirdar D Heath SA Geller 1984 Homology between the female paraurethral (Skene's) glands and the prostate. Immunohistochemical demonstration Arch Pathol Lab Med 108 423 425
37. PA Burch JK Breen JC Buckner DA Gastineau JA Kaur RL Laus DJ Padley MV Peshwa HC Pitot RL Richardson BJ Smits P Sopapan G Strang FH Valone S Vuk-Pavlovic 2000 Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer Clin Cancer Res 6 2175 2182
38. N Hida Y Maeda K Katagiri H Takasu M Harada K Itoh 2002 A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation Cancer Immunol Immunotherapy 51 219 228